Adents, Microsoft Partner on Track & Trace Cloud Platform
News Nov 04, 2016
Indentations and Microsoft have decided to combine their skills to build and market a cloud platform called indentations Prodigi. Indentations Prodigi is the only level traceability solution 4 can centrally manage regulatory requirements of the pharmaceutical industry and to give laboratories and converters the ability to take advantage of the mass of information from the serialization process and Track & Trace.
Beyond regulatory compliance, ADENTS Prodigi opens new horizons in terms of:
• Identification and traceability
• Fight against counterfeiting
• Monitoring of the productivity of production sites
• Customer experience and personalized communication
• Data visualization and analysis in real time
Expertise of ADENTS, identification and traceability are supported by a global trend to regulation. Over 80% of world production of medicines will be forced to the identification unit 2019. This new process offers extraordinary opportunities in terms of visibility on the lives of pharmaceuticals and requires a major challenge in terms of data management.
Indentations Prodigi relies on Microsoft Azure advanced technology and enables pharmaceutical companies to generate, exchange and safely control the vast amount of data generated by the identification unit. Data Analytics tools (including MS Power BI) and Machine Learning are also available on the platform ADENTS Prodigi, providing powerful analysis capabilities of these new information fields.
Indentations Prodigi is developed and supported by a joint team indentations and Microsoft, and is intended to host third-party business applications using the data of the platform. Indentations Prodigi is the solution to meet the new regulations but above all, to finally exploit new data and better manage activity.
"Our alliance with the leader in enterprise BI solutions will change the situation on the world market of the unit identification. Indeed, it empowers industrial companies to create and operate the digital profile of their products, with a mine information for all stakeholders in the product life cycle, " explains Christophe Devins, CEO and founder of ADENTS.
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE